Clontech Licenses CRISPR/CAS9 Technology From Broad Institute
News Oct 28, 2014
"Clontech is pleased to be able to provide innovative tools for CRISPR/Cas9 gene editing under our Guide-it™ brand," commented Carol Lou, General Manager of Clontech Laboratories, Inc. "We believe that CRISPR/Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use. It is destined to become as valuable and widely utilized as RNAi; perhaps more so."
Clontech's initial product offering includes Guide-it kits for in vitro production and screening of single guide RNAs (sgRNAs) and a method to confirm the presence of targeted mutations using direct PCR and Clontech's Guide-it Resolvase enzyme.
Gene Immunotherapy Approach Prevents and Reverses Symptoms of Multiple SclerosisNews
Researchers used a viral vector to deliver a gene encoding a myelin sheath protein to the liver, thereby inducing robust and durable immune tolerance in mice by preventing T cells from attacking the myelin sheath.READ MORE
Genetic Code of Neuronal Communication Determines Cell TypeNews
The findings should help scientists sort out the bewildering array of neurons that are intertwined in the brain.READ MORE
Human Microbiome Project: Millions of New Genes IdentifiedNews
A new study of the human microbiome, the trillions of microbial organisms that live on and within our bodies, has uncovered millions of previously unknown genes.READ MORE